Johnson & Johnson's (NYSE:JNJ) med device segment had a pretty sleepy first quarter, with 0.7% revenue growth (about 1% operationally). But management highlighted some new and exciting opportunities for this underloved division, including a huge potential tailwind from the Affordable Care Act (also known as Obamacare). Watch the video below for more on this exciting growth opportunity.


David Williamson owns shares of Johnson & Johnson. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.